PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Journal of Gastrointestinal Infections 2022; 12(02): 101-105
DOI: 10.1055/s-0042-1759738
Original Article

Sofosbuvir-Velpatasvir Full Dose in Chronic Hepatitis C in End-Stage Renal Disease: An Observational Study from a Himalayan Region

Aadil Ashraf 
1   Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India
,
Altaf Shah
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Muzafar Wani
3   Department of Nephrology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Mushtaq Khan
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
G.M. Gulzar
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Shaheena Parveen
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Jaswinder Singh
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Hilal Dar
4   Government Medical College (GMC) Baramulla, Baramulla, Jammu and Kashmir, India
,
Nadeem Ahmad
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints


Preview

Abstract

Background Treatment of chronic hepatitis C (CHC) in the setting of chronic kidney disease and end-stage renal disease (ESRD) is challenging.

Objectives We planned to evaluate the efficacy and safety of full dose of combination of sofosbuvir-velpatasvir in the treatment of CHC in patients with ESRD or those on maintenance hemodialysis.

Methods The prospective observational study was conducted in a tertiary care center in North India where all patients with chronic kidney disease (CKD) were assessed. Those with hepatitis C virus (HCV) antibody positivity underwent testing for HCV ribonucleic acid and were treated if eligible. Full dose of sofosbuvir-velpatasvir was administered daily for 12 weeks (or 24 weeks for decompensated liver disease).

Results Of the 162 patients (mean age: 43.08 ± 12.08 years, 114 males), 125 were on regular hemodialysis. Twenty-four (15%) had evidence of liver cirrhosis, out of which four patients had evidence of decompensation. One hundred forty-two patients (87.6%) had an early virological response. Most patients, 160 (98.7%), obtained end of therapy viral clearance and sustained virological response at 12 weeks after therapy. Two patients died, and rest of the patients completed therapy. The adverse effects noticed were nausea (20%), vomiting (18%), headache (10%), and weakness (7%).

Conclusion A combination of sofosbuvir and velpatasvir is effective and safe in treating CHC in the setting of CKD.

Keywords

hepatitis C - cirrhosis - chronic kidney disease - end-stage renal disease - direct acting antiviral

Ethical Statement

The institutional ethics committee (IEC-SKIMS) cleared the study with reference number RP 86/2020. Informed written consent was obtained before inclusion.


Authors' Contributions

Conceptualization: A.A., A.S., M.W. Methodology, investigation, and original draft: A.A. Project administration and supervision: A.S. Data curation, visualization, and software: M.K., G.M.G. Initial draft: S.P. Resources: J.S. Data curation: H.D. Validation: N.A. All authors approved the final version.


Data Availability Statement

The data associated can be obtained from the corresponding author on a reasonable request.




Publikationsverlauf

Eingereicht: 31. Juli 2022

Angenommen: 03. Oktober 2022

Artikel online veröffentlicht:
22. September 2023

© 2023. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India